Spyre Therapeutics, INC 10-Q quarterly reports

Spyre Therapeutics filed its Q1 2026 10-Q, detailing a net loss of $69 million and significant R&D investment, while advancing its IBD and rheumatic disease programs.

Spyre Therapeutics reported a significantly reduced net loss in Q3 2025, driven by a decrease in CVR liability and a gain from an asset sale, while advancing its inflammatory bowel disease and rheumatic disease pipeline into Phase 2 trials.

Spyre Therapeutics reported a net loss of $36.7 million for Q2 2025, advancing its IBD and RD pipeline with positive clinical trial progress and a strong cash position.

Spyre Therapeutics reports its financial results for the first quarter of 2025, highlighting ongoing clinical trials and pipeline development.

Spyre Therapeutics has amended its quarterly report for the period ended September 30, 2024, due to a misapplication of U.S. GAAP related to the calculation of net loss per share and has identified a material weakness in internal control over financial reporting.

Spyre Therapeutics has amended its second-quarter 2024 report to correct a misapplication of U.S. GAAP related to the calculation of net loss per share and has identified a material weakness in internal control over financial reporting.

Spyre Therapeutics has amended its first quarter 2024 financial report to correct an error in calculating loss per share and has identified a material weakness in internal controls related to this issue.

Spyre Therapeutics' third quarter 2024 report details financial results and progress in their IBD therapeutic pipeline.

Spyre Therapeutics' second quarter 2024 report details financial results and advancements in their inflammatory bowel disease (IBD) therapeutic pipeline.

Spyre Therapeutics reports a net loss of $43.9 million for the first quarter of 2024, alongside significant progress in its IBD pipeline development.